<p>隨着全球市場在利率預期和持續的人工智能熱潮中航行，道瓊斯指數、標準普爾 500 指數和納斯達克綜合指數等主要指數已達到歷史新高。在這種樂觀和經濟變革的背景下，內部持股比例高的成長型公司通常表明強大的內部信心和與股東利益的一致性，使其對尋求在波動市場環境中獲得穩定的投資者具有吸引力。</p>
<h3>全球內部持股比例高的十大成長型公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股比例</strong></td>
<td><strong>盈利增長</strong></td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>33.9%</td>
<td>84.6%</td>
</tr>
<tr>
<td>Pharma Mar (BME:PHM)</td>
<td>11.8%</td>
<td>44.2%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>30.3%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>33.9%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>38.4%</td>
<td>63.7%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>35.2%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>11.8%</td>
<td>50.7%</td>
</tr>
<tr>
<td>Elliptic Laboratories (OB:ELABS)</td>
<td>24.4%</td>
<td>97.5%</td>
</tr>
<tr>
<td>CD Projekt (WSE:CDR)</td>
<td>29.7%</td>
<td>43.5%</td>
</tr>
<tr>
<td>Ascentage Pharma Group International (SEHK:6855)</td>
<td>12.8%</td>
<td>91.9%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們內部持股比例高的快速成長全球公司篩選器中的 844 只股票的完整列表。</p>
<p>我們將查看篩選工具中的一些最佳選擇。</p>
<h2>北京海博思創科技 (SHSE:688411)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 北京海博思創科技有限公司專注於在中國、歐洲、北美和澳大利亞設計、開發、集成和運營能源存儲電站，市值為 328.7 億人民幣。</p>
<p><strong>運營：</strong> 收入細分（單位：百萬人民幣）：</p>
<p><strong>內部持股比例：</strong> 22.6%</p>
<p><strong>盈利增長預測：</strong> 年均 26.9%。</p>
<p>北京海博思創科技有望實現強勁增長，預計收入年均增長 29.4%，超過市場平均水平。盈利也預計將顯著增長，年均增長 26.88%。該公司最近與北京第四範式科技的合資企業旨在利用人工智能提升能源存儲的技術優勢和市場覆蓋。儘管股價波動較大，但戰略聯盟可能在沒有近期顯著內部交易活動的情況下增強長期前景。</p>
<ul>
<li>通過閲讀我們的分析師估計報告，深入瞭解北京海博思創科技的表現。</li>
<li>我們精心準備的估值報告顯示，北京海博思創科技的股價可能過高。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3bfd9198-7ed0-45a8-8819-04c19d1aa84b/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3bfd9198-7ed0-45a8-8819-04c19d1aa84b/chart/ownership-breakdown"/></p>
<p>截至 2025 年 9 月的 SHSE:688411 股權結構</p>
<h2>源傑科技 (SHSE:688498)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 源傑科技有限公司（股票代碼：SHSE:688498）在半導體行業運營，市值為 319.5 億人民幣。</p>
<p><strong>運營：</strong> 源傑科技的收入來自半導體行業的各個細分領域。</p>
<p><strong>內部持股比例：</strong> 28.0%</p>
<p><strong>盈利增長預測：</strong> 年均 68.2%。</p>
<p>源傑科技有望實現顯著增長，預計盈利年均增長 68.16%，超過中國市場。收入也預計年均增長 42%。最近的盈利報告顯示，淨收入從去年 1075 萬人民幣增長至 4626 萬人民幣。儘管股價波動較大，且未來的股本回報率預測較低，但沒有近期的內部交易表明對未來表現的信心。</p>
<ul>
<li>在這份增長報告中解鎖我們對源傑科技股票分析的全面見解。</li>
<li>我們的估值報告顯示，源傑科技可能被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/e1b67cd8-756e-41ed-a2b2-44d64189c77d/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/e1b67cd8-756e-41ed-a2b2-44d64189c77d/chart/ownership-breakdown"/></p>
<p>截至 2025 年 9 月的 SHSE:688498 股權結構</p>
<h2>內蒙古富瑞醫學科技 (SZSE:300049)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 內蒙古富瑞醫學科技有限公司在醫學科技行業運營，專注於開發和製造醫療產品，市值為 181.6 億人民幣。</p>
<p><strong>運營：</strong> 內蒙古富瑞醫學科技有限公司通過專注於開發和製造醫療產品來產生收入。</p>
<p><strong>內部持股比例：</strong> 16.1%</p>
<p><strong>盈利增長預測：</strong> 年均 45%。</p>
<p>內蒙古富瑞醫學科技有望實現顯著增長，預計盈利年均增長 45%，超過中國市場的預測。收入預計年均增長 22.1%，儘管最近的報告顯示淨收入從 7536 萬人民幣下降至 5193 萬人民幣。儘管股價波動較大，且未來的股本回報率預測較低為 15.1%，但沒有內部交易活動表明內部信心穩定。</p>
<ul>
<li>在我們的盈利增長報告中更深入地瞭解內蒙古富瑞醫學科技的潛力。</li>
<li>根據我們的估值報告，內蒙古富瑞醫學科技的股價可能偏高。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b77fa0ad-6c66-4515-9cd9-e43b415df394/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b77fa0ad-6c66-4515-9cd9-e43b415df394/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 9 月的 SZSE:300049 盈利和收入增長</p>
<h2>抓住機會</h2>
<ul>
<li>點擊這裏解鎖我們 844 家快速成長全球公司內部持股比例高的全面列表。</li>
<li>準備好採取不同的方法嗎？發現 8 家在 COVID 後生存並蓬勃發展的公司，它們具備生存特朗普關税的正確要素。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不意圖提供財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有引用的預測收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>

海博思創

源傑科技

<p>隨着全球市場在利率預期和人工智能熱潮中創下歷史新高，擁有高內部持股的成長型公司正吸引投資者的關注。值得注意的公司包括北京海博思創、源傑科技和內蒙古富瑞醫療科技，這些公司都顯示出良好的盈利增長預期。儘管股價波動，但內部持股表明了強大的內部信心。文章強調了內部持股在評估公司穩定性和增長潛力中的重要性，同時提供了一份包含 844 家高內部持股快速增長公司的名單</p>

<p>As global markets navigate through interest rate expectations and the ongoing artificial intelligence boom, major indices such as the Dow Jones, S&amp;P 500, and Nasdaq Composite have reached record highs. Amid this backdrop of optimism and economic shifts, growth companies with high insider ownership often signal strong internal confidence and alignment with shareholder interests, making them appealing to investors seeking stability in a fluctuating market environment.</p>
<div class="lb-trans"><p>隨着全球市場在利率預期和持續的人工智能熱潮中航行，道瓊斯指數、標準普爾 500 指數和納斯達克綜合指數等主要指數已達到歷史新高。在這種樂觀和經濟變革的背景下，內部持股比例高的成長型公司通常表明強大的內部信心和與股東利益的一致性，使其對尋求在波動市場環境中獲得穩定的投資者具有吸引力。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership Globally</h3>
<div class="lb-trans"><h3>全球內部持股比例高的十大成長型公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>33.9%</td>
<td>84.6%</td>
</tr>
<tr>
<td>Pharma Mar (BME:PHM)</td>
<td>11.8%</td>
<td>44.2%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>30.3%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>33.9%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>38.4%</td>
<td>63.7%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>35.2%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>11.8%</td>
<td>50.7%</td>
</tr>
<tr>
<td>Elliptic Laboratories (OB:ELABS)</td>
<td>24.4%</td>
<td>97.5%</td>
</tr>
<tr>
<td>CD Projekt (WSE:CDR)</td>
<td>29.7%</td>
<td>43.5%</td>
</tr>
<tr>
<td>Ascentage Pharma Group International (SEHK:6855)</td>
<td>12.8%</td>
<td>91.9%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股比例</strong></td>
<td><strong>盈利增長</strong></td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>33.9%</td>
<td>84.6%</td>
</tr>
<tr>
<td>Pharma Mar (BME:PHM)</td>
<td>11.8%</td>
<td>44.2%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>30.3%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>33.9%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>38.4%</td>
<td>63.7%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>35.2%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>11.8%</td>
<td>50.7%</td>
</tr>
<tr>
<td>Elliptic Laboratories (OB:ELABS)</td>
<td>24.4%</td>
<td>97.5%</td>
</tr>
<tr>
<td>CD Projekt (WSE:CDR)</td>
<td>29.7%</td>
<td>43.5%</td>
</tr>
<tr>
<td>Ascentage Pharma Group International (SEHK:6855)</td>
<td>12.8%</td>
<td>91.9%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 844 stocks from our Fast Growing Global Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們內部持股比例高的快速成長全球公司篩選器中的 844 只股票的完整列表。</p>
</div><p>We're going to check out a few of the best picks from our screener tool.</p>
<div class="lb-trans"><p>我們將查看篩選工具中的一些最佳選擇。</p>
</div><h2>Beijing HyperStrong Technology (SHSE:688411)</h2>
<div class="lb-trans"><h2>北京海博思創科技 (SHSE:688411)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Beijing HyperStrong Technology Co., Ltd. specializes in the design, development, integration, and operation of energy storage power stations across China, Europe, North America, and Australia with a market cap of CN¥32.87 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 北京海博思創科技有限公司專注於在中國、歐洲、北美和澳大利亞設計、開發、集成和運營能源存儲電站，市值為 328.7 億人民幣。</p>
</div><p><strong>Operations:</strong> Revenue Segments (in millions of CN¥):</p>
<div class="lb-trans"><p><strong>運營：</strong> 收入細分（單位：百萬人民幣）：</p>
</div><p><strong>Insider Ownership:</strong> 22.6%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 22.6%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 26.9% p.a.</p>
<div class="lb-trans"><p><strong>盈利增長預測：</strong> 年均 26.9%。</p>
</div><p>Beijing HyperStrong Technology is poised for robust growth, with revenue expected to increase by 29.4% annually, surpassing market averages. Earnings are also forecasted to grow significantly at 26.88% per year. The company's recent joint venture with Beijing Fourth Paradigm Technology aims to leverage AI in energy storage, enhancing its technological edge and market reach. Despite high volatility in share price, the strategic alliance could bolster long-term prospects without substantial insider trading activity noted recently.</p>
<div class="lb-trans"><p>北京海博思創科技有望實現強勁增長，預計收入年均增長 29.4%，超過市場平均水平。盈利也預計將顯著增長，年均增長 26.88%。該公司最近與北京第四範式科技的合資企業旨在利用人工智能提升能源存儲的技術優勢和市場覆蓋。儘管股價波動較大，但戰略聯盟可能在沒有近期顯著內部交易活動的情況下增強長期前景。</p>
</div><ul>
<li>Get an in-depth perspective on Beijing HyperStrong Technology's performance by reading our analyst estimates report here.</li>
<li>Our expertly prepared valuation report Beijing HyperStrong Technology implies its share price may be too high.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過閲讀我們的分析師估計報告，深入瞭解北京海博思創科技的表現。</li>
<li>我們精心準備的估值報告顯示，北京海博思創科技的股價可能過高。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3bfd9198-7ed0-45a8-8819-04c19d1aa84b/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/3bfd9198-7ed0-45a8-8819-04c19d1aa84b/chart/ownership-breakdown"/></p>
<p>SHSE:688411 Ownership Breakdown as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 SHSE:688411 股權結構</p>
</div><h2>Yuanjie Semiconductor Technology (SHSE:688498)</h2>
<div class="lb-trans"><h2>源傑科技 (SHSE:688498)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Yuanjie Semiconductor Technology Co., Ltd. (ticker: SHSE:688498) operates in the semiconductor industry and has a market capitalization of CN¥31.95 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 源傑科技有限公司（股票代碼：SHSE:688498）在半導體行業運營，市值為 319.5 億人民幣。</p>
</div><p><strong>Operations:</strong> Yuanjie Semiconductor Technology's revenue is derived from various segments within the semiconductor industry.</p>
<div class="lb-trans"><p><strong>運營：</strong> 源傑科技的收入來自半導體行業的各個細分領域。</p>
</div><p><strong>Insider Ownership:</strong> 28.0%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 28.0%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 68.2% p.a.</p>
<div class="lb-trans"><p><strong>盈利增長預測：</strong> 年均 68.2%。</p>
</div><p>Yuanjie Semiconductor Technology is set for substantial growth, with earnings projected to rise by 68.16% annually, outpacing the Chinese market. Revenue is also expected to grow at a robust 42% per year. Recent earnings reports show significant improvements, with net income reaching CNY 46.26 million from CNY 10.75 million last year. Despite high share price volatility and low forecasted return on equity, no recent insider trading suggests confidence in future performance.</p>
<div class="lb-trans"><p>源傑科技有望實現顯著增長，預計盈利年均增長 68.16%，超過中國市場。收入也預計年均增長 42%。最近的盈利報告顯示，淨收入從去年 1075 萬人民幣增長至 4626 萬人民幣。儘管股價波動較大，且未來的股本回報率預測較低，但沒有近期的內部交易表明對未來表現的信心。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Yuanjie Semiconductor Technology stock in this growth report.</li>
<li>Our valuation report here indicates Yuanjie Semiconductor Technology may be overvalued.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這份增長報告中解鎖我們對源傑科技股票分析的全面見解。</li>
<li>我們的估值報告顯示，源傑科技可能被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/e1b67cd8-756e-41ed-a2b2-44d64189c77d/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/e1b67cd8-756e-41ed-a2b2-44d64189c77d/chart/ownership-breakdown"/></p>
<p>SHSE:688498 Ownership Breakdown as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 SHSE:688498 股權結構</p>
</div><h2>Inner Mongolia Furui Medical Science (SZSE:300049)</h2>
<div class="lb-trans"><h2>內蒙古富瑞醫學科技 (SZSE:300049)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Inner Mongolia Furui Medical Science Co., Ltd. operates in the medical science industry with a focus on developing and manufacturing medical products, and it has a market cap of CN¥18.16 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 內蒙古富瑞醫學科技有限公司在醫學科技行業運營，專注於開發和製造醫療產品，市值為 181.6 億人民幣。</p>
</div><p><strong>Operations:</strong> Inner Mongolia Furui Medical Science Co., Ltd. generates revenue through its focus on developing and manufacturing medical products.</p>
<div class="lb-trans"><p><strong>運營：</strong> 內蒙古富瑞醫學科技有限公司通過專注於開發和製造醫療產品來產生收入。</p>
</div><p><strong>Insider Ownership:</strong> 16.1%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 16.1%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 45% p.a.</p>
<div class="lb-trans"><p><strong>盈利增長預測：</strong> 年均 45%。</p>
</div><p>Inner Mongolia Furui Medical Science is poised for significant growth, with earnings expected to increase by 45% annually, surpassing the Chinese market's forecast. Revenue is projected to grow at 22.1% per year, though recent reports show a decline in net income from CNY 75.36 million to CNY 51.93 million compared to last year. Despite volatile share prices and a low future return on equity of 15.1%, no insider trading activity indicates stable internal confidence.</p>
<div class="lb-trans"><p>內蒙古富瑞醫學科技有望實現顯著增長，預計盈利年均增長 45%，超過中國市場的預測。收入預計年均增長 22.1%，儘管最近的報告顯示淨收入從 7536 萬人民幣下降至 5193 萬人民幣。儘管股價波動較大，且未來的股本回報率預測較低為 15.1%，但沒有內部交易活動表明內部信心穩定。</p>
</div><ul>
<li>Take a closer look at Inner Mongolia Furui Medical Science's potential here in our earnings growth report.</li>
<li>According our valuation report, there's an indication that Inner Mongolia Furui Medical Science's share price might be on the expensive side.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的盈利增長報告中更深入地瞭解內蒙古富瑞醫學科技的潛力。</li>
<li>根據我們的估值報告，內蒙古富瑞醫學科技的股價可能偏高。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b77fa0ad-6c66-4515-9cd9-e43b415df394/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/b77fa0ad-6c66-4515-9cd9-e43b415df394/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:300049 Earnings and Revenue Growth as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 SZSE:300049 盈利和收入增長</p>
</div><h2>Taking Advantage</h2>
<div class="lb-trans"><h2>抓住機會</h2>
</div><ul>
<li>Unlock our comprehensive list of 844 Fast Growing Global Companies With High Insider Ownership by clicking here.</li>
<li>Ready For A Different Approach? Uncover 8 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏解鎖我們 844 家快速成長全球公司內部持股比例高的全面列表。</li>
<li>準備好採取不同的方法嗎？發現 8 家在 COVID 後生存並蓬勃發展的公司，它們具備生存特朗普關税的正確要素。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不意圖提供財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有引用的預測收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>
</div>

全球增長型股票受到內部人士高度信任